

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 338 295 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
27.08.2003 Bulletin 2003/35

(51) Int Cl.7: **A61M 5/172, A61M 5/145**

(21) Application number: **03251117.2**

(22) Date of filing: **25.02.2003**

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT SE SI SK TR**
Designated Extension States:
AL LT LV MK RO

(30) Priority: **26.02.2002 US 360401 P**

(71) Applicant: **Lifescan, Inc.**
Milpitas, California 95035-6312 (US)

(72) Inventors:
• **Bylund, Adam David**
Fremont, California 94539 (US)
• **Durban, William Jefferey**
Pleasanton, California 94566 (US)

- **Wardle, Michael D.**
San Jose, California 95138 (US)
- **Long, Karen M.**
San Jose, California 95125 (US)
- **McClusky, Joseph**
Sharon, Massachusetts 02067 (US)
- **Kraft, Ulrich**
65719 Hofheim (DE)
- **Ebner, Manfred**
61440 Oberursel (DE)
- **Steine, Matthias**
Inverness IV2 3QG (GB)

(74) Representative: **Mercer, Christopher Paul et al**
Carpmaels & Ransford
43, Bloomsbury Square
London WC1A 2RA (GB)

(54) **Systems for remotely controlling medication infusion and analyte monitoring**

(57) Devices, systems and methods are provided for remotely controlling medication delivery to a patient by means of a medication infusion pump, such as a subcutaneous infusion pump, and for remotely controlling the monitoring of one or more physiological fluid analytes such as by a percutaneous measurement device. The systems of the present invention include a medication infusion pump and a hand-held "fob" for the remote control of the infusion pump and/or measurement device. In addition to remotely controlling the insulin pump and the measurement device, the fob provides for the

consolidation of blood chemistry data and insulin delivery data over a period of time and maintains such consolidated data for immediate and later retrieval by the user or a physician. The methods of the present invention allow a user to customize and optimize an insulin bolus delivery protocol, *i.e.*, bolus volume and delivery duration, by factoring in or compensating for the user's current or substantially current blood chemistry evaluation and/or the user's anticipated and/or actual carbohydrate intake.

EP 1 338 295 A1

